A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(10): 1185-1198, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-2065335
ABSTRACT
Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pyridines
/
Adenocarcinoma
/
Antineoplastic Agents, Hormonal
/
Antibodies, Monoclonal, Humanized
/
Prostatic Neoplasms, Castration-Resistant
/
Immune Checkpoint Inhibitors
/
Anilides
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
/
Male
Language:
English
Journal:
Future Oncol
Year:
2022
Document Type:
Article
Affiliation country:
Fon-2021-1096
Similar
MEDLINE
...
LILACS
LIS